Natalia Geyvandova
Stavropol Regional Clinical Oncology Center(RU)Stavropol State Medical University(RU)
Publications by Year
Research Areas
Hepatitis C virus research, Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies, Liver Disease and Transplantation, Hepatitis Viruses Studies and Epidemiology
Most-Cited Works
- → A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D(2023)195 cited
- → Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial(2022)144 cited
- → Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial(2023)69 cited
- → The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities(2022)56 cited
- → Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial(2024)55 cited
- → Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study(2022)32 cited
- → Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study(2022)19 cited
- → Results of multicenter double blind randomized placebo-controlled post-registration clinical study (IV phase)(2017)10 cited
- → LBO-004 Final results of MYR301: a randomised phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis delta and 96 weeks of posttreatment follow-up(2025)8 cited
- → Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study(2023)6 cited